Eli Lilly (LLY)

The most recent research report on the "Avascular Necrosis Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts,

Can any company pose a serious challenge to Eli Lilly in the weight-loss market?

There is light at the end of the tunnel.

SpaceX looks like a rocket, but don't fly too close to the sun. Here's why Eli Lilly is likely a better stock to own.

This particular sector may suit cautious and aggressive investors.

The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals.

Wall Street analysts expect market-beating returns from healthcare and communication services stocks over the next year.

Eli Lilly's pipeline is an embarrassment of riches.

It is finally bouncing back after several challenging years.

Explore how two healthcare ETFs stack up in cost, yield, and strategy, with one fund emphasizing innovation and charitable impact.

Huang has lofty expectations for Marvell Technology.

Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.

An upcoming trial result could change how investors think about the weight-loss drug market.

Expense ratios, asset size, and portfolio strategy set these two healthcare ETFs apart, yet their risk and dividend profiles tell a different story.

Expense ratios, dividend yields, and risk profiles set these healthcare ETFs apart. See how their strategies shape long-term performance for investors.

The Vanguard Health Care ETF (VHT) and the iShares Global Healthcare ETF (IXJ) both target health care stocks, but they are tailored to different investor needs. One emphasizes broad, low-cost U.S. exposure, while the other adds global reach in a sector shaped by drug pricing, patent cycles, regulation, and medical innovation.

Micron Technology just became the 12th-biggest company in the world, bigger than Berkshire Hathaway. UBS sees another 56% upside as June 24 earnings near.

David Ricks was addressing the pharmaceutical titan's latest hot product.

Eli Lilly signs drug development deals with Hanmi and Haisco as Retevmo Phase 3 data show an 83% cut in recurrence risk.

Lilly shares soared more than 18% in May.

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical...

Micron's share price doubled in 48 days.